title: The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion.
abstract: OBJECTIVE
  This study aimed to assess the prognostic value of CD4+CD25+ T lymphocyte in peripheral blood among breast cancer patients treated with adoptive T lymphocytes immunotherapy.
  
  
  METHODS
  217 patients participated in the follow-up study. CD4+CD25+ proportion was measured by flow cytometry in peripheral T cells. The median survival was estimated by Kaplan-Meier curve, Log-rank test and Cox hazard proportion regression model, between groups of CD4+CD25+ proportion more than 5% and less than or equal to 5% in peripheral T cells.
  
  
  RESULTS
  Peripheral CD4+CD25+ T lymphocytes had not a relationship with progression-free survival. It was featured that above 5% peripheral CD4+CD25+ proportion of T cells was related with the median overall survival by a shorten of 51 months (p < 0.05) with the HR 1.65 (95%CI 1.04, 2.62). Above 5% CD4+CD25+proportion of T cells produced the HR to be 1.76 (95%CI 1.07, 2.87) In stage 0-II patients, and 3.59 (95%CI 1.05, 12.29) in triple negative breast cancer patients.
  
  
  CONCLUSIONS
  Cellular immunity restoration recovered by adoptive T cell infusions which resulted in less proportion of peripheral CD4+CD25+T lymphocytes could be a potential prognostic indicator among early stage and triple negative patients.
authors.affiliation: Beijing Key Laboratory of Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 10038, China.
authors.forename: Qing-Kun
authors.initials: QK
authors.lastname: Song
authors.affiliation: Beijing Key Laboratory of Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 10038, China.|Department of Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.|Department of Surgery, Duke University Medical Center, Durham, NC 27710, United States of America.
authors.forename: Jun
authors.initials: J
authors.lastname: Ren
authors.affiliation: Beijing Key Laboratory of Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 10038, China.|Department of Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Xin-Na
authors.initials: XN
authors.lastname: Zhou
authors.affiliation: Beijing Key Laboratory of Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 10038, China.|Department of Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Xiao-Li
authors.initials: XL
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Guo-Hong
authors.initials: GH
authors.lastname: Song
authors.affiliation: Department of Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Li-Jun
authors.initials: LJ
authors.lastname: Di
authors.affiliation: Department of Medical Oncology, Peking University Cancer Hospital & Institute, Beijing 100142, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Yu
authors.affiliation: Department of Surgery, Duke University Medical Center, Durham, NC 27710, United States of America.
authors.forename: Amy
authors.initials: A
authors.lastname: Hobeika
authors.affiliation: Department of Medicine, Duke University Medical Center, Durham, NC 27710, United States of America.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Morse
authors.affiliation: Beijing Key Laboratory of Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 10038, China.
authors.forename: Yan-Hua
authors.initials: YH
authors.lastname: Yuan
authors.affiliation: Beijing Key Laboratory of Therapeutic Cancer Vaccines, Capital Medical University Cancer Center, Beijing Shijitan Hospital, Beijing 10038, China.
authors.forename: Hua-Bing
authors.initials: HB
authors.lastname: Yang
authors.affiliation: Department of Surgery, Duke University Medical Center, Durham, NC 27710, United States of America.
authors.forename: Herbert Kim
authors.initials: HK
authors.lastname: Lyerly
mesh_terms: D000328:Adult; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism*; D055612:Cytokine-Induced Killer Cells / Q000637:transplantation*; D003713:Dendritic Cells / Q000637:transplantation*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D053645:Interleukin-2 Receptor alpha Subunit / Q000378:metabolism; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D017063:Outcome Assessment, Health Care / Q000379:methods / Q000706:statistics & numerical data; D011379:Prognosis; D016016:Proportional Hazards Models; D064726:Triple Negative Breast Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*
chemical_list: D053645:Interleukin-2 Receptor alpha Subunit
keywords: CD4+CD25+ T lymphocyte; adoptive cell therapy; early stage breast cancer; prognosis; triple negative breast cancer